Table 2.

Hazard ratio (HR) and corresponding 95% confidence interval (CI) for progression-free survival and overall survival in 163 patients with stage III–IV oropharyngeal squamous cell carcinoma

	Patients	Overall survival			Progression-free survival
		Events	HR (95% CI)a	HR (95% CI)b	Events	HR (95% CI)a	HR (95% CI)b
Sex
Man	117	64	Reference	Reference	69	Reference	Reference
Woman	46	26	1.03 (0.64–1.63)	1.05 (0.65–1.70)	29	1.20 (0.77–1.87)	1.28 (0.81–2.02)
Age (years)
< 60	40	20	Reference	Reference	22	Reference	Reference
60–69	57	26	1.00 (0.54–1.83)	1.06 (0.57–1.98)	31	1.11 (0.63–1.97)	1.18 (0.66–2.15)
≥ 70	66	44	1.91 (1.10–3.33)	1.47 (0.83–2.64)	45	1.80 (1.05–3.07)	1.54 (0.88–2.58)
T stagec
T1-T2	75	35	Reference	Reference	37	Reference	Reference
T3-T4	88	55	1.74 (1.13–2.69)	1.42 (0.89–2.25)	61	1.76 (1.16–2.68)	1.32 (0.84–2.08)
N stagec
N0-N1	45	29	Reference	Reference	30	Reference	Reference
N2	105	51	0.79 (0.50–1.26)	1.20 (0.71–2.02)	58	0.86 (0.55–1.34)	1.13 (0.69–1.85)
N3	13	10	2.29 (1.10–4.78)	2.87 (1.34–6.14)	10	2.29 (1.10–4.73)	2.65 (1.26–5.59)
HPV-status
Negative	110	76	Reference	Reference	82	Reference	Reference
Positive	46	13	0.30 (0.16–0.54)	0.43 (0.23–0.81)	14	0.29 (0.16–0.51)	0.39 (0.21–0.72)
Surgery
No	73	40	Reference		43	Reference
Yes	90	50	1.17 (0.75–1.82)		55	1.08 (0.70–1.65)
LINE-1 methylation
≥ 55%	80	34	Reference	Reference	40	Reference	Reference
35–54%	48	28	1.60 (0.96–2.67)	1.46 (0.85–2.49)	29	1.41 (0.86–2.31)	1.25 (0.75–2.07)
< 35%	35	28	3.21 (1.89–5.45)	2.76 (1.48–5.12)	29	3.19 (1.92–5.30)	2.39 (1.35–4.24)

^aEstimated from Cox proportional hazards model, adjusted for study center, sex, and age

^bFurther adjusted for T stage, N stage, HPV status, and LINE-1 methylation. ^cTNM staging according to the American Joint Committee on Cancer 7th Edition